Navigation Links
Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
Date:2/2/2009

owed by difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA) which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of potential U.S. Food and Drug Administration (FDA) approval of Intermezzo(R); and the expected timing of commercialization and launch of Intermezzo(R); the estimated net loss of Transcept at December 31, 2008; the pro forma cash, cash equivalents and marketable securities balance of the combined entity as of December 31, 2008; the ability of Transcept to commercialize Intermezzo(R) utilizing the resources of the combined company; expected payments to lenders; expected merger transaction costs; future presentations of management, including planned quarterly conference calls; and the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; mai
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Ticket ... Grande concert tickets. This popular ticket exchange is ... , Ariana Grande is nearing that next step in the ... considered a superstar in the music and entertainment business, but ... released her second straight No. 1 album, will hit the ...
(Date:9/20/2014)... The print component of “Work-Life Balance” is being ... with a circulation of approximately 97,000 copies and ... is distributed nationally through a vast social media ... sites and partner outlets. To explore the digital ... , The publication features an exclusive Mediaplanet interview ...
(Date:9/20/2014)... -- As flu season approaches, the best way to ... flu shot and a checkup, according to an infectious ... vaccinate people against the flu, and also address other ... may provide flu shots for their customers, but they ... medical director of infection prevention and control for the ...
(Date:9/20/2014)... 2014 New PharmaPoint Drug Evaluation ... to 2023?. The asthma market saw very slow ... become saturated with relatively efficacious standard therapies, such ... corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, ... However, the launch of seven novel targeted biologic ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2
... fluid in the ears does not improve speech, hearing or ... two reasons for ear tube surgery -- persistent, severe ear ... otherwise healthy child. Doctors have been concerned that if surgery ... long-term developmental impairment. ,"We were led to the conclusion ...
... companies to drop a historic case in South Africa ... according to leading non-governmental organizations (NGOs). ,The 39 ... legalized use and import of generic medicines free from ... biggest in the world, had challenged the order on ...
... Researchers in the UK say that wound healing in depressed ... These and related reports find a place in the latest ... have direct and indirect effects on the rate of wound ... have been shown to affect the immune system, which may ...
... J. Keefe of Duke University Medical School in Durham, North ... of the Journal of pain. Patients who use religion or ... can reduce their pain and boost their sense of well ... expect that people coping with chronic illness or chronic pain ...
... exercising reduces the risk of heart disease. But almost everyone ... But recent study shows that skinny people are also prone ... important factors in the genesis of various heart ailments. ... Canada, who headed the study, says that heart disease does ...
... which was developed to fight resistant bacteria, is already ... resistance. ,The drug linezolid is used to treat ... the old standby antibiotic vancomycin. The hope has been ... problem of vancomycin-resistant enterococci infections. But in the April ...
Cached Medicine News:Health News:Researchers urge caution in using ear tube surgery 2Health News:Researchers urge caution in using ear tube surgery 3Health News:India to benefit from pharma companies' move 2
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... and ORLANDO, Fla. , ... supporting Inspire therapy continues to grow, with the publication ... published on-line in Otolaryngology – Head and ... causes a worsening of both objective and subjective measures ... directly attribute Inspire therapy for the reduction in obstructive ...
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... (Nasdaq: VRUS ) announced today the pricing ... its common stock at an offering price of $46.33 ... selling 2,300,000 shares and the selling stockholders are selling ... deducting the underwriting discount and estimated offering expenses, of ...
... investor meeting held today in New York, NY, Watson ... update on its Global businesses, including a detailed overview ... Global Generics and Global Brands businesses, and an update ... the meeting, the Company provided its preliminary 2011 financial ...
Cached Medicine Technology:Pharmasset Prices Public Offering of Common Stock 2Pharmasset Prices Public Offering of Common Stock 3Watson Presents Outlook for Continued Long Term Growth 2Watson Presents Outlook for Continued Long Term Growth 3Watson Presents Outlook for Continued Long Term Growth 4Watson Presents Outlook for Continued Long Term Growth 5Watson Presents Outlook for Continued Long Term Growth 6Watson Presents Outlook for Continued Long Term Growth 7Watson Presents Outlook for Continued Long Term Growth 8
Delicate membrane hook/pick with hook on side of instrument for engaging membranes. 20 gauge shaft with balanced titanium handle. Dark finish for reduced glare. Left....
0.5 mm angled tip. Round knurled handle with dull finish. Tip angle: 150 degrees....
0.2 mm, 90o angled tip. Flat smooth handle with polished finish....
Nucleus manipulator facilitates lens rotation during phacoemulsification....
Medicine Products: